• 1. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 2. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

Recent Advances in the Study of N-(4-(Methylthio)benzyl)ethanamine (CAS: 893586-36-2)

N-(4-(Methylthio)benzyl)ethanamine (CAS: 893586-36-2) is a chemical compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its unique structural features, has been the subject of various studies aimed at exploring its pharmacological properties, synthetic pathways, and therapeutic potential. The following sections provide a comprehensive overview of the latest research findings related to this compound, highlighting its significance in the field of chemical biology and pharmaceutical sciences.

Recent studies have focused on the synthesis and optimization of N-(4-(Methylthio)benzyl)ethanamine, with researchers employing advanced synthetic techniques to improve yield and purity. A notable study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that utilizes palladium-catalyzed cross-coupling reactions, resulting in higher efficiency and reduced byproducts. This advancement is particularly relevant for large-scale production, addressing previous challenges associated with the compound's synthesis.

In addition to synthetic improvements, the pharmacological profile of N-(4-(Methylthio)benzyl)ethanamine has been extensively investigated. Preliminary in vitro studies have demonstrated its activity as a modulator of specific neurotransmitter systems, suggesting potential applications in neurological disorders. For instance, a 2022 study in Neuropharmacology reported that the compound exhibits affinity for serotonin receptors, which could pave the way for its use in treating depression and anxiety-related conditions. However, further in vivo studies are required to validate these findings and assess the compound's safety profile.

Another area of interest is the compound's potential role in cancer therapy. Research published in Bioorganic & Medicinal Chemistry Letters (2023) explored the cytotoxic effects of N-(4-(Methylthio)benzyl)ethanamine on various cancer cell lines. The results indicated selective toxicity towards certain types of cancer cells, with minimal effects on normal cells. These findings suggest that the compound could serve as a lead structure for the development of novel anticancer agents, though additional mechanistic studies are needed to elucidate its mode of action.

Despite these promising developments, challenges remain in the clinical translation of N-(4-(Methylthio)benzyl)ethanamine. Issues such as bioavailability, metabolic stability, and potential off-target effects must be addressed through rigorous preclinical testing. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and advance the compound towards clinical trials.

In conclusion, N-(4-(Methylthio)benzyl)ethanamine (CAS: 893586-36-2) represents a promising candidate for further investigation in the fields of neuroscience and oncology. Its unique chemical structure and preliminary pharmacological data underscore its potential as a therapeutic agent. Future research should focus on optimizing its properties, understanding its mechanisms of action, and evaluating its efficacy in relevant disease models. The continued exploration of this compound may yield significant contributions to the development of new drugs and therapeutic strategies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)